1 Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
2 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Chron Respir Dis. 2017 May;14(2):151-160. doi: 10.1177/1479972316680846. Epub 2016 Jan 1.
Epidemiological studies have identified a trend in the development of depressive and anxiety disorders following a diagnosis of chronic obstructive pulmonary disease (COPD). However, the relationship between COPD and subsequent bipolar disorder remains unclear. From January 1, 2000, we identified adult patients with COPD from the Taiwan National Health Insurance Research Database. A nationwide population-based study was conducted; 46,778 COPD patients and 46,778 age-, sex-, and comorbidity-matched subjects between 2000 and 2011 were enrolled. The two cohorts were followed up till December 31, 2011 and observed for occurrence of bipolar disorder. We observed the COPD and comparison cohorts for 263,020 and 267,895 person-years, respectively, from 2000 to 2011. The incidence rate for bipolar disorder was 1.6/1000 person-years in the COPD cohort and 1.2/1000 person-years in the comparison cohort ( p < 0.001). After multivariate adjustment, the hazard ratio (HR) for subsequent bipolar disorder among the COPD patients was 1.42 (95% confidence interval [CI], 1.22-1.64; p < 0.001). In the COPD patients, short-acting beta-agonists (SABAs) was associated with a significantly increased risk of bipolar disorder development (HR = 1.83, 95% CI = 1.25-2.69, p = 0.002). Other COPD medications were not associated with the risk of bipolar disorder development. The study results indicate that COPD may be an independent risk factor for the development of bipolar disorder. The regular use of SABAs might increase the risk of bipolar disorder in COPD patients.
流行病学研究表明,在诊断出慢性阻塞性肺疾病(COPD)后,抑郁和焦虑障碍的发展呈上升趋势。然而,COPD 与随后发生的双相情感障碍之间的关系尚不清楚。从 2000 年 1 月 1 日起,我们从台湾全民健康保险研究数据库中确定了 COPD 成年患者。进行了一项全国性的基于人群的研究;纳入了 2000 年至 2011 年间的 46778 例 COPD 患者和 46778 例年龄、性别和合并症匹配的患者。两个队列分别随访至 2011 年 12 月 31 日,观察双相情感障碍的发生情况。我们观察 COPD 和对照组队列分别从 2000 年到 2011 年共 263020 和 267895 人年。COPD 队列中双相情感障碍的发生率为 1.6/1000 人年,对照组为 1.2/1000 人年(p<0.001)。多变量调整后,COPD 患者发生双相情感障碍的风险比(HR)为 1.42(95%置信区间 [CI],1.22-1.64;p<0.001)。在 COPD 患者中,短效β-激动剂(SABA)与双相情感障碍发展的风险显著增加相关(HR=1.83,95%CI=1.25-2.69,p=0.002)。其他 COPD 药物与双相情感障碍发展的风险无关。研究结果表明,COPD 可能是双相情感障碍发展的独立危险因素。SABA 的常规使用可能会增加 COPD 患者发生双相情感障碍的风险。